Understanding how bacteria resist phage attacks to improve treatment options for infections.
Mechanisms of reverse transcriptase mediated phage resistance in Enterobacteriaceae
This study is looking at how we can use viruses that target bacteria, called bacteriophages, to help fight tough infections caused by bacteria that don't respond to regular antibiotics, and it aims to find out how these bacteria protect themselves so we can create better treatments for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10901546 on NIH RePORTER |
What this research studies
This research explores how multidrug-resistant Enterobacteriaceae, which pose a significant public health threat, can be controlled by bacteriophages. It investigates the mechanisms that these bacteria use to defend against phage attacks, particularly focusing on reverse transcriptase genes that may play a role in this defense. By understanding these interactions, the research aims to develop phage therapies as alternatives to traditional antibiotics, potentially offering new treatment options for patients with severe infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by multidrug-resistant Enterobacteriaceae.
Not a fit: Patients with infections caused by bacteria that are not Enterobacteriaceae or those who are not infected may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative phage therapies that effectively treat infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research has shown promise in using phage therapy to combat antibiotic-resistant infections, indicating that this approach has potential for success.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Tang, Stephen — Columbia University Health Sciences
- Study coordinator: Tang, Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.